April 9, 2010 - Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technologies, announced that the first patients have been enrolled in the INNOVATION trial, which will assess the safety of a new stent graft system, called INCRAFT™, to treat abdominal aortic aneurysm (AAA). An estimated 27 million people worldwide have abdominal aortic aneurysms. Left untreated, all aneurysms will eventually rupture, and more than 80% of aneurysms that rupture result in death. In the U.S. alone, approximately 15,000 people die every year due to an AAA rupture... Cordis' Press Release (JNJ) -
Tuesday, June 1, 2010
Cordis : First Patients Enrolled In Trial of New Stent Graft System To Treat Abdominal Aortic Aneurysm
April 9, 2010 - Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technologies, announced that the first patients have been enrolled in the INNOVATION trial, which will assess the safety of a new stent graft system, called INCRAFT™, to treat abdominal aortic aneurysm (AAA). An estimated 27 million people worldwide have abdominal aortic aneurysms. Left untreated, all aneurysms will eventually rupture, and more than 80% of aneurysms that rupture result in death. In the U.S. alone, approximately 15,000 people die every year due to an AAA rupture... Cordis' Press Release (JNJ) -
